NCT02418195View on ClinicalTrials.gov

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

PHASE2CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

April 20, 2015

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Major Depressive Disorder
Interventions
DRUG

ketamine

IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT02418195 - miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome | Biotech Hunter | Biotech Hunter